Labcorp Holdings Yönetim

Yönetim kriter kontrolleri 4/4

Labcorp Holdings CEO'su Adam Schechter, Nov2019 tarihinde atandı, in görev süresi 11.58 yıldır. in toplam yıllık tazminatı $ 15.98M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.6% maaş ve 91.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.1% ine doğrudan sahiptir ve bu hisseler $ 21.10M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 9.7 yıldır.

Anahtar bilgiler

Adam Schechter

İcra Kurulu Başkanı

US$16.0m

Toplam tazminat

CEO maaş yüzdesi	8.6%
CEO görev süresi	5yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	9.7yrs

Son yönetim güncellemeleri

Recent updates

Here's Why It's Unlikely That Laboratory Corporation of America Holdings' (NYSE:LH) CEO Will See A Pay Rise This Year

May 08

Laboratory Corporation of America Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72

Apr 30

Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72

Apr 15

Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark

Apr 06

Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear

Apr 01

Laboratory Corporation of America Holdings (NYSE:LH) Will Pay A Dividend Of $0.72

Feb 25

We Think You Can Look Beyond Laboratory Corporation of America Holdings' (NYSE:LH) Lackluster Earnings

Feb 22

An Intrinsic Calculation For Laboratory Corporation of America Holdings (NYSE:LH) Suggests It's 48% Undervalued

Feb 21

Laboratory Corporation of America Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72

Jan 31

Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly

Jan 30

Laboratory Corporation of America Holdings' (NYSE:LH) Dividend Will Be $0.72

Jan 15

Some Shareholders Feeling Restless Over Laboratory Corporation of America Holdings' (NYSE:LH) P/E Ratio

Jan 05

Laboratory Corporation: Multiple Updates, Same Investment Conclusion

Dec 02

Laboratory Corp.: Rate On Capital Deployed Contracting, Hold

Sep 14

Laboratory Corporation: Trying To Create Value By Spinning Out Fortrea

Jul 05

Newsflash: Laboratory Corporation of America Holdings (NYSE:LH) Analysts Have Been Trimming Their Revenue Forecasts

Jul 04

Are Investors Undervaluing Laboratory Corporation of America Holdings (NYSE:LH) By 43%?

Jun 23

Laboratory Corporation: Predictability Of Cash Flows Less Visible

Jun 21

Is It Too Late To Consider Buying Laboratory Corporation of America Holdings (NYSE:LH)?

May 26

CEO Tazminat Analizi

Adam Schechter'un ücretlendirmesi Labcorp Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$436m
Jun 30 2024	n/a	n/a	US$450m
Mar 31 2024	n/a	n/a	US$399m
Dec 31 2023	US$16m	US$1m	US$379m
Sep 30 2023	n/a	n/a	US$583m
Jun 30 2023	n/a	n/a	US$677m
Mar 31 2023	n/a	n/a	US$789m
Dec 31 2022	US$15m	US$1m	US$1b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$21m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$3b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$15m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$845m
Jun 30 2020	n/a	n/a	US$362m
Mar 31 2020	n/a	n/a	US$321m
Dec 31 2019	US$6m	US$208k	US$824m
Sep 30 2019	n/a	n/a	US$755m
Jun 30 2019	n/a	n/a	US$853m
Mar 31 2019	n/a	n/a	US$896m
Dec 31 2018	US$301k	n/a	US$884m
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$290k	n/a	US$1b

Tazminat ve Piyasa: Adam 'ın toplam tazminatı ($USD 15.98M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 12.64M ).

Tazminat ve Kazançlar: Adam 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Adam Schechter (59 yo)

5yrs

Görev süresi

US$15,979,355

Tazminat

Mr. Adam H. Schechter serves as the President, CEO & Chairman of Laboratory Corporation of America Holdings. Mr. Adam serves as President & Chief Executive Officer at Labcorp Holdings Inc. since November...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Schechter	President	5yrs	US$15.98m	0.10% $ 21.1m
Glenn Eisenberg	CFO & Executive VP	10.4yrs	US$4.96m	0.037% $ 7.5m
Mark Schroeder	Executive VP	1.5yrs	US$3.80m	0.0060% $ 1.2m
Brian Caveney	EVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer	1.5yrs	US$3.48m	0.033% $ 6.7m
Anita Graham	Executive VP & Chief Human Resources Officer	1.6yrs	US$2.56m	0.00035% $ 70.6k
Peter Wilkinson	Senior VP & Chief Accounting Officer	5.6yrs	Veri yok	0.0025% $ 504.5k
Akinbolade Oyegunwa	Executive VP and Chief Information & Technology Officer	less than a year	Veri yok	0.0032% $ 643.8k
Christin O'Donnell	Vice President of Investor Relations	no data	Veri yok	Veri yok
Sandra van der Vaart	Executive VP	5.8yrs	Veri yok	0.0044% $ 886.0k
Amy Summy	Executive VP & Chief Marketing Officer	4.7yrs	Veri yok	0.0047% $ 958.6k
Marcia Eisenberg	Enterprise Chief Scientific Officer & Senior VP	no data	Veri yok	Veri yok
Deborah Sesok-Pizzini	Chief Medical Officer	3.8yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: LH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Schechter	President	11.6yrs	US$15.98m	0.10% $ 21.1m
Peter Neupert	Independent Director	11.8yrs	US$357.87k	0.014% $ 2.9m
Kerrii Anderson	Independent Director	18.5yrs	US$340.73k	0.017% $ 3.4m
Garheng Kong	Lead Independent Director	10.9yrs	US$375.73k	0.014% $ 2.9m
Richelle Parham	Independent Director	8.8yrs	US$341.44k	0.010% $ 2.1m
D. Gilliland	Independent Director	10.6yrs	US$330.01k	0.010% $ 2.1m
Jeffrey Davis	Independent Director	4.9yrs	US$344.30k	0.0043% $ 873.9k
Paul Rothman	Independent Director	1.4yrs	US$208.42k	0.00087% $ 175.6k
Kathryn Wengel	Independent Director	3.7yrs	US$330.01k	0.0027% $ 553.0k
Kirsten Kliphouse	Independent Director	2.1yrs	US$330.01k	0.0016% $ 318.9k

9.7yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.7 yıldır).

Labcorp Holdings Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Executive VP & Chief Marketing Officer notifies of intention to sell stock

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

President notifies of intention to sell stock

CFO & Executive VP recently sold US$3.4m worth of stock

CFO & Executive VP notifies of intention to sell stock

Insider recently sold US$2.8m worth of stock

Recent updates

Executive VP & Chief Marketing Officer notifies of intention to sell stock

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Upcoming dividend of US$0.72 per share

President notifies of intention to sell stock

Labcorp Holdings Inc.'s (NYSE:LH) Price In Tune With Earnings

Third quarter 2024 earnings: EPS misses analyst expectations

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Is Labcorp Holdings (NYSE:LH) Using Too Much Debt?

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.

When Should You Buy Labcorp Holdings Inc. (NYSE:LH)?

Laboratory Corporation: Difficult To Eye Long-Term Compounding Ability

Upcoming dividend of US$0.72 per share

CFO & Executive VP recently sold US$3.4m worth of stock

CFO & Executive VP notifies of intention to sell stock

Insider recently sold US$2.8m worth of stock

Insider notifies of intention to sell stock

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024

Investors Still Waiting For A Pull Back In Labcorp Holdings Inc. (NYSE:LH)

Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024

Laboratory Corporation: Limited Upside Visibility, Reiterate Hold

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials

When Should You Buy Labcorp Holdings Inc. (NYSE:LH)?

Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio

Upcoming dividend of US$0.72 per share

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy

Here's Why It's Unlikely That Laboratory Corporation of America Holdings' (NYSE:LH) CEO Will See A Pay Rise This Year

Laboratory Corporation of America Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Dividend of US$0.72 announced

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Executive VP notifies of intention to sell stock

Labcorp Launches Weight Loss Management Testing Solutions

Laboratory Corporation of America Holdings (NYSE:LH) Will Pay A Dividend Of $0.72

CFO & Executive VP recently sold US$4.4m worth of stock

We Think You Can Look Beyond Laboratory Corporation of America Holdings' (NYSE:LH) Lackluster Earnings

An Intrinsic Calculation For Laboratory Corporation of America Holdings (NYSE:LH) Suggests It's 48% Undervalued

Upcoming dividend of US$0.72 per share

Full year 2023 earnings: EPS misses analyst expectations

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Laboratory Corporation of America Holdings' (NYSE:LH) Dividend Will Be $0.72

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Some Shareholders Feeling Restless Over Laboratory Corporation of America Holdings' (NYSE:LH) P/E Ratio

Laboratory Corporation: Multiple Updates, Same Investment Conclusion

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Upcoming dividend of US$0.72 per share at 1.5% yield